Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer

Published:2015-08-13 Issue:2 Volume:21 Page:240-247
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kaira Kyoichi,Sunaga Noriaki,Imai Hisao,Kamide Yosuke,Koga Yasuhiko,Ono Akihiro,Kuwako Tomohito,Masuda Tomomi,Hisada Takeshi,Ishizuka Tamotsu,Yamada Masanobu

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-015-0883-7.pdf

Reference20 articles.

1. Azzoli CG, Temin S, Aliff T et al (2011) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831

2. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

3. Tani N, Yabuki M, Komuro S et al (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 35:1121–1133

4. Kurata T, Okamoto I, Tamura K et al (2007) Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs 25:499–504

5. Takeda K, Takifuji N, Negoro S et al (2007) Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 25:377–383

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor;Journal of Clinical Medicine;2021-09-17

2. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin;Lung Cancer;2018-01

3. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells;Molecules;2017-10-26